NEWS RELEASE

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

2025-03-12

PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

The live webcast will be available online at **http://ir.inovio.com/events-and-presentations/default.aspx**. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit **www.inovio.com**.

Contacts

Media: Jennie Willson, (267) 429-8567, **communications@inovio.com**
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, **investor.relations@inovio.com**

View original content to download multimedia:**https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-18-2025-302400150.html**

SOURCE INOVIO Pharmaceuticals, Inc.